- Home
- GRCE
as 04-25-2025 4:00pm EST
Stocks
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 32.1M | IPO Year: | N/A |
| Target Price: | $12.00 | AVG Volume (30 days): | 22.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.16 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.75 - $4.97 | Next Earning Date: | 05-15-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest GRACE THERAPEUTICS INC News
GRCE Breaking Stock News: Dive into GRCE Ticker-Specific Updates for Smart Investing
GlobeNewswire
17 days ago
Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104
GlobeNewswire
2 months ago
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors
GlobeNewswire
2 months ago
Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
Zacks Small Cap Research
2 months ago
GRCE: STRIVE-ON Results Reported
GlobeNewswire
2 months ago
Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update
Pharmaceutical Technology
2 months ago
Grace Therapeutics secures $15m for GTx-104 pre-commercial development
MT Newswires
2 months ago
Grace Therapeutics Shares Rise After Private Placement Financing of up to $30 Million
Benzinga
3 months ago
Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study
Compare GRCE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GRCE GRACE THERAPEUTICS INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.